Sickle Cell Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Blood Transfusion, Bone Marrow Transplant), By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030

Sickle Cell Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Blood Transfusion, Bone Marrow Transplant), By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030


Sickle Cell Disease Treatment Market Growth & Trends

The global sickle cell disease treatment market size is expected to reach USD 7.42 billion by 2030, registering a CAGR of 15.7% during the forecast period, according to a new report by Grand View Research, Inc. Several factors including increased investments in R&D, a growing target population, increasing awareness programs, and favorable government initiatives are anticipated to drive the growth. According to the European Sickle Cell Federation, around 70 thousand people are living with sickle cell disease (SCD) in Europe.

The introduction of noninvasive, technologically advanced, and digital technologies to facilitate the detection of SCD is set to assist in overcoming the barriers associated with targeted sickle cell diagnosis and treatment management. Presently developed POC devices are based on methodologies such as densitometry, lateral flow immunoassay, and microfluidic electrophoresis. The increase in the diagnosis rate of disease will further facilitate growth.

Available treatments for sickle cell disease usually provide symptomatic relief and palliative care. These treatment methods generally include blood transfusions, bone marrow transplants, and pharmacotherapy. However, a bone marrow transplant is the only potentially curative treatment recommended only to a small percentage of patients. Moreover, increasing approval of novel drugs such as Oxbryta by Global Blood Therapeutics, Inc.;Endari by Emmaus Medical, Inc.; and PYRUKYND by Agios Pharmaceuticals, Inc. is expected to drive the market growth.

Increasing collaborations between market players and government and non-government organizations are anticipated to fuel market growth over the forecast period. For instance, in February 2021, Novartis AG and Bill & Melinda Gates Foundation collaborated to develop novel gene therapy for sickle cell disease. According to the agreement, Bill & Melinda Gates Foundation will provide funding to support the development of novel therapy to cure SKD.

High-unmet medical needs, a strong pipeline, and a growing patient pool are key factors expected to influence market growth. In recent years, demand for cost-effective drugs and gene therapies for sickle cell anemia has increased owing to the unavailability of a permanent cure and the risks associated with bone marrow transplants. Companies such as bluebird bio, Inc.; Bellicum Phamaceuticals, Inc.; and Gamida Cell are actively involved in the development of new effective gene therapies for sickle cell disease treatment, which is expected to increase the treatment rate in the coming years.

Expected launches of late-stage pipeline drugs such as voxelotor, crizanlizumab, Altemia, and rivipansel are projected to drive the sickle cell disease industry during the forecast period. Healthcare initiatives undertaken by respective economies are crucial for curbing the financial burden of the disease as well as for increasing access to healthcare facilities and providing various services for early diagnosis, subsequent treatment, and palliative care.

Sickle Cell Disease Treatment Market Report Highlights
  • Based on treatment, the blood transfusion segment dominated the market in 2023. The high number of procedures and mostly adopted therapeutic options to manage SCD support the segment share
  • Based on end-use, the hospital segment held the largest market share in 2023 as hospitals served as primary centers for treatment and diagnosis of the disease
  • North America dominated the global market with a share of more than 37.87% in 2023, whereas the Asia Pacific region is projected to grow at the fastest CAGR over the forecast period
  • Key market players are undertaking several strategies such as new product development, mergers & acquisitions to increase their market share over the forecast period.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1 Report Scope and Objectives
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Treatment segment
1.1.1.2 End-use segment
1.2 Regional Scope
1.3 Estimates and Forecast Timeline
1.4 Objectives
1.4.1 Objective - 1
1.4.2 Objective - 2
1.4.3 Objective - 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 GVR’s Internal Database
1.6.3 Secondary Sources
1.6.4 Primary research
1.7 Information or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List of Secondary Sources
1.11 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.2.1 Treatment
2.2.2 End-use
2.2.3 Region
2.3 Competitive Insights
Chapter 3 Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.2 Sickle cell disease treatment Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Increasing prevalence of disease
3.2.1.2 Awareness programs and services
3.2.1.3 Presence of reimbursement policies
3.2.2 Market Restraint Analysis
3.2.2.1 Adverse effects and risks related to the treatment procedure
3.3 Sickle cell disease treatment Market: Business Environment Analysis Tools
3.3.1 PORTER’S Five Forces Analysis
3.3.1.1 Threat of new entrants
3.3.1.2 Bargaining power of suppliers
3.3.1.3 Bargaining power of buyers
3.3.1.4 Competitive rivalry
3.3.1.5 Threat of substitutes
3.3.2 PESTEL Analysis
3.3.2.1 Political & Legal
3.3.2.2 Economic & Social
3.3.2.3 Technological
3.4 Penetration & Growth Prospect Mapping
3.5 Impact of COVID-19 on the sickle cell disease treatment market
Chapter 4 Sickle Cell Disease Treatment Market: Treatment Analysis
4.1 Sickle Cell Disease Treatment Treatment Market Share Analysis, 2018 & 2030
4.2 Sickle Cell Disease Treatment Treatment Market: Segment Dashboard:
4.3 Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Treatment Segment
4.3.1 Bone Marrow Transplant
4.3.1.1 Bone marrow transplant market, 2018 - 2030 (USD Million)
4.3.2 Blood Transfusion
4.3.2.1 Blood transfusion market, 2018 - 2030 (USD Million)
4.3.3 Pharmacotherapy
4.3.3.1 Pharmacotherapy market, 2018 - 2030 (USD Million)
Chapter 5 Sickle Cell Disease Treatment Market: End-use Analysis
5.1 Sickle Cell Disease Treatment End-use Mode Market Share Analysis, 2018 & 2030
5.2 Sickle Cell Disease Treatment End-use Mode Market: Segment Dashboard
5.3 Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the End-use Mode Segment
5.3.1 Hospitals
5.3.1.1 Hospitals market, 2018 - 2030 (USD Million)
5.3.2 Specialty Clinics
5.3.2.1 Specialty Clinics market, 2018 - 2030 (USD Million)
5.3.3 Others
5.3.3.1 Others market, 2018 - 2030 (USD Million)
Chapter 6 Sickle Cell Disease Treatment Market: Regional Analysis
6.1. Sickle Cell Disease Market Share By Region, 2023 & 2030
6.2. North America
6.2.1. SWOT Analysis
6.2.2. North America Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.2.3. U.S.
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Competitive Scenario
6.2.3.4. Regulatory Framework
6.2.3.5. U.S. Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.2.4. Canada
6.2.4.1. Key Country Dynamics
6.2.4.2. Target Disease Prevalence
6.2.4.3. Competitive Scenario
6.2.4.4. Regulatory Framework
6.2.4.5. Canada Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.3. Europe
6.3.1. SWOT Analysis
6.3.2. Europe Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.3.3. UK
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Competitive Scenario
6.3.3.4. Regulatory Framework
6.3.3.5. UK Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.3.4. Germany
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. Competitive Scenario
6.3.4.4. Regulatory Framework
6.3.4.5. Germany Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.3.5. France
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Competitive Scenario
6.3.5.4. Regulatory Framework
6.3.5.5. France Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.3.6. Italy
6.3.6.1. Key Country Dynamics
6.3.6.2. Target Disease Prevalence
6.3.6.3. Competitive Scenario
6.3.6.4. Regulatory Framework
6.3.6.5. Italy Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.3.7. Spain
6.3.7.1. Key Country Dynamics
6.3.7.2. Target Disease Prevalence
6.3.7.3. Competitive Scenario
6.3.7.4. Regulatory Framework
6.3.7.5. Spain Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.3.8. Denmark
6.3.8.1. Key Country Dynamics
6.3.8.2. Target Disease Prevalence
6.3.8.3. Competitive Scenario
6.3.8.4. Regulatory Framework
6.3.8.5. Denmark Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.3.9. Sweden
6.3.9.1. Key Country Dynamics
6.3.9.2. Target Disease Prevalence
6.3.9.3. Competitive Scenario
6.3.9.4. Regulatory Framework
6.3.9.5. Sweden Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.3.10. Norway
6.3.10.1.Key Country Dynamics
6.3.10.2.Target Disease Prevalence
6.3.10.3.Competitive Scenario
6.3.10.4.Regulatory Framework
6.3.10.5.Norway Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. SWOT Analysis
6.4.2. Asia Pacific Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.4.3. Japan
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Competitive Scenario
6.4.3.4. Regulatory Framework
6.4.3.5. Japan Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.4.4. China
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Competitive Scenario
6.4.4.4. Regulatory Framework
6.4.4.5. China Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.4.5. India
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Competitive Scenario
6.4.5.4. Regulatory Framework
6.4.5.5. India Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.4.6. Australia
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Competitive Scenario
6.4.6.4. Regulatory Framework
6.4.6.5. Australia Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.4.7. Thailand
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. Competitive Scenario
6.4.7.4. Regulatory Framework
6.4.7.5. Thailand Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.4.8. South Korea
6.4.8.1. Key Country Dynamics
6.4.8.2. Target Disease Prevalence
6.4.8.3. Competitive Scenario
6.4.8.4. Regulatory Framework
6.4.8.5. South Korea Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.5. Latin America
6.5.1. SWOT Analysis
6.5.2. Latin America Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.5.3. Brazil
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Competitive Scenario
6.5.3.4. Regulatory Framework
6.5.3.5. Brazil Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.5.4. Mexico
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Competitive Scenario
6.5.4.4. Regulatory Framework
6.5.4.5. Mexico Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.5.5. Argentina
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Competitive Scenario
6.5.5.4. Regulatory Framework
6.5.5.5. Argentina Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.6. MEA
6.6.1. SWOT Analysis
6.6.2. MEA Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.6.3. South Africa
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Competitive Scenario
6.6.3.4. Regulatory Framework
6.6.3.5. South Africa Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.6.4. Saudi Arabia
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Competitive Scenario
6.6.4.4. Regulatory Framework
6.6.4.5. Saudi Arabia Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.6.5. UAE
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Competitive Scenario
6.6.5.4. Regulatory Framework
6.6.5.5. UAE Sickle Cell Disease Market, 2018 - 2030 (USD Million)
6.6.6. Kuwait
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Competitive Scenario
6.6.6.4. Regulatory Framework
6.6.6.5. Kuwait Sickle Cell Disease Market, 2018 - 2030 (USD Million)
Chapter 7 Competitive Analysis
7.1 Company Categorization
7.2 Strategy Mapping
7.2.1 New product launch
7.2.2 Partnerships
7.2.3 Acquisition
7.2.4 Collaboration
7.3 Company Profiles
7.3.1 Novartis AG
7.3.1.1 Company overview
7.3.1.2 Financial performance
7.3.1.3 Product benchmarking
7.3.1.4 Strategic initiatives
7.3.2 Pfizer Inc.
7.3.2.1 Company overview
7.3.2.2 Financial performance
7.3.2.3 Product benchmarking
7.3.2.4 Strategic initiatives
7.3.3 bluebird bio, Inc.
7.3.3.1 Company overview
7.3.3.2 Financial performance
7.3.3.3 Product benchmarking
7.3.3.4 Strategic initiatives
7.3.4 GlycoMimetics
7.3.4.1 Company overview
7.3.4.2 Financial performance
7.3.4.3 Product benchmarking
7.3.4.4 Strategic initiatives
7.3.5 Emmaus Medical, Inc.
7.3.5.1 Company overview
7.3.5.2 Financial performance
7.3.5.3 Product benchmarking
7.3.5.4 Strategic initiatives
7.3.6 Bristol-Myers Squibb Company
7.3.6.1 Company overview
7.3.6.2 Financial performance
7.3.6.3 Product benchmarking
7.3.6.4 Strategic initiatives
7.3.7 CRISPR Therapeutics
7.3.7.1 Company overview
7.3.7.2 Financial performance
7.3.7.3 Product benchmarking
7.3.7.4 Strategic initiatives
7.3.8 Graphite Bio, Inc.
7.3.8.1 Company overview
7.3.8.2 Financial performance
7.3.8.3 Product benchmarking
7.3.8.4 Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings